@article{SianHulsmannRiederer2021,
  author    = {Sian-Hulsmann, Jeswinder and Riederer, Peter},
  title     = {The nigral coup in Parkinson's Disease by α-synuclein and its associated rebels},
  series = {Cells},
  volume    = {10},
  journal   = {Cells},
  number    = {3},
  issn      = {2073-4409},
  doi       = {10.3390/cells10030598},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-234073},
  year      = {2021},
  abstract  = {The risk of Parkinson's disease increases with age. However, the etiology of the illness remains obscure. It appears highly likely that the neurodegenerative processes involve an array of elements that influence each other. In addition, genetic, endogenous, or exogenous toxins need to be considered as viable partners to the cellular degeneration. There is compelling evidence that indicate the key involvement of modified α-synuclein (Lewy bodies) at the very core of the pathogenesis of the disease. The accumulation of misfolded α-synuclein may be a consequence of some genetic defect or/and a failure of the protein clearance system. Importantly, α-synuclein pathology appears to be a common denominator for many cellular deleterious events such as oxidative stress, mitochondrial dysfunction, dopamine synaptic dysregulation, iron dyshomeostasis, and neuroinflammation. These factors probably employ a common apoptotic/or autophagic route in the final stages to execute cell death. The misfolded α-synuclein inclusions skillfully trigger or navigate these processes and thus amplify the dopamine neuron fatalities. Although the process of neuroinflammation may represent a secondary event, nevertheless, it executes a fundamental role in neurodegeneration. Some viral infections produce parkinsonism and exhibit similar characteristic neuropathological changes such as a modest brain dopamine deficit and α-synuclein pathology. Thus, viral infections may heighten the risk of developing PD. Alternatively, α-synuclein pathology may induce a dysfunctional immune system. Thus, sporadic Parkinson's disease is caused by multifactorial trigger factors and metabolic disturbances, which need to be considered for the development of potential drugs in the disorder.},
  language  = {en}
}
@article{MolochnikovRabeyDobronevskyetal.2012,
  author    = {Molochnikov, Leonid and Rabey, Jose M. and Dobronevsky, Evgenya and Bonuccelli, Ubaldo and Ceravolo, Roberto and Frosini, Daniela and Gr{\"u}nblatt, Edna and Riederer, Peter and Jacob, Christian and Aharon-Peretz, Judith and Bashenko, Yulia and Youdim, Moussa B. H. and Mandel, Silvia A.},
  title     = {A molecular signature in blood identifies early Parkinson's disease},
  series = {Molecular Neurodegeneration},
  volume    = {7},
  journal   = {Molecular Neurodegeneration},
  number    = {26},
  doi       = {10.1186/1750-1326-7-26},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134508},
  year      = {2012},
  abstract  = {Background: The search for biomarkers in Parkinson's disease (PD) is crucial to identify the disease early and monitor the effectiveness of neuroprotective therapies. We aim to assess whether a gene signature could be detected in blood from early/mild PD patients that could support the diagnosis of early PD, focusing on genes found particularly altered in the substantia nigra of sporadic PD. Results: The transcriptional expression of seven selected genes was examined in blood samples from 62 early stage PD patients and 64 healthy age-matched controls. Stepwise multivariate logistic regression analysis identified five genes as optimal predictors of PD: p19 S-phase kinase-associated protein 1A (odds ratio [OR] 0.73; 95\% confidence interval [CI] 0.60-0.90), huntingtin interacting protein-2 (OR 1.32; CI 1.08-1.61), aldehyde dehydrogenase family 1 subfamily A1 (OR 0.86; 95\% CI 0.75-0.99), 19 S proteasomal protein PSMC4 (OR 0.73; 95\% CI 0.60-0.89) and heat shock 70-kDa protein 8 (OR 1.39; 95\% CI 1.14-1.70). At a 0.5 cut-off the gene panel yielded a sensitivity and specificity in detecting PD of 90.3 and 89.1 respectively and the area under the receiving operating curve (ROC AUC) was 0.96. The performance of the five-gene classifier on the de novo PD individuals alone composing the early PD cohort (n = 38), resulted in a similar ROC with an AUC of 0.95, indicating the stability of the model and also, that patient medication had no significant effect on the predictive probability (PP) of the classifier for PD risk. The predictive ability of the model was validated in an independent cohort of 30 patients at advanced stage of PD, classifying correctly all cases as PD (100\% sensitivity). Notably, the nominal average value of the PP for PD (0.95 (SD = 0.09)) in this cohort was higher than that of the early PD group (0.83 (SD = 0.22)), suggesting a potential for the model to assess disease severity. Lastly, the gene panel fully discriminated between PD and Alzheimer's disease (n = 29). Conclusions: The findings provide evidence on the ability of a five-gene panel to diagnose early/mild PD, with a possible diagnostic value for detection of asymptomatic PD before overt expression of the disorder.},
  language  = {en}
}